GoKawiilEli Lilly, Novo Nordisk cite aging clocks showing GLP-1 drugs slow biological aging
Eli Lilly and Novo Nordisk report that patients on their GLP-1 drugs show slower biological aging according to molecular 'aging clocks' measuring DNA changes and protein levels. Separately, MIT Technology Review named Energy Dome among its 10 Climate Tech Companies to Watch for 2026, citing its system that stores renewable energy using compressed carbon dioxide rather than underground caverns.
GoKawiil's interpretation of the reporting above, not reported fact.
The GLP-1 findings feed speculation that these drugs may address fundamental aging processes rather than just weight or blood sugar, though the connection between aging-clock readings and real-world longevity benefits remains unproven. Energy Dome's geology-independent approach could make grid-scale energy storage more deployable worldwide, potentially easing renewable energy's intermittency problem if the technology proves cost-effective at scale.
- Eli Lilly and Novo Nordisk link GLP-1 drugs to slower biological aging via molecular clock measurements
- The aging-clock evidence is preliminary and doesn't yet confirm GLP-1 drugs extend lifespan
- Energy Dome's compressed CO2 battery avoids the geological constraints of traditional compressed-air storage
Source: technologyreview.com — Thomas Macaulay, 2026-10-07
Published there as: “The Download: weight-loss drugs slowing aging and carbon dioxide batteries”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.